Set-back for Hikma's generic Advair Diskus ANDA

22 September 2020
hikma-big

Generic drugmaker Hikma Pharmaceuticals (LSE: HIK) has received a minor complete response letter (CRL) from the US Food and Drug Administration (FDA) in relation to its abbreviated new drug application (ANDA) for its US generic version of Advair Diskus (fluticasone propionate and salmeterol inhalation powder: VR315 [US]).

This is a copy of GlaxoSmithKline’s (LSE: GSK) top-selling asthma treatment that was developed in partnership with Vectura (LSE: VEC), a leading inhalation contract development and manufacturing organization (CDMO).

London-listed Hikma says it is working closely with the FDA to quickly address the small number of questions raised in the minor CRL. Once answered, Hikma can expect to receive a response from the FDA within 90 days. Both Hikma and Vectura are committed to bringing this important product to the US market and remain confident in the submission.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics